Milestone Pharmaceuticals Earnings Call Transcripts
Fiscal Year 2026
-
CARDAMYST launched as the first new PSVT treatment in decades, offering rapid, at-home relief and strong clinical data. The company is targeting 10,000 key providers with 60 sales reps, secured initial payer coverage, and is advancing a phase III trial for AFib-RVR, supported by $200M in cash and a clear path to break-even.
-
CARDAMYST, a novel nasal spray for PSVT, launched with strong commercial support and no branded competition, targeting 2 million US patients. Early uptake is promising, with expansion plans for atrial fibrillation and ex-US markets via partnerships.
Fiscal Year 2025
-
FDA approval and U.S. launch of CARDAMYST marked a pivotal year, with strong initial prescription activity and a robust $200 million cash position supporting operations into late 2027. Early payer coverage is limited, but commercial and Medicare access are expected to expand in 2026–2027.
-
FDA approved Cardamyst nasal spray for PSVT, marking the first new therapy in over 30 years. The product demonstrated rapid efficacy, a strong safety profile, and is expected to reduce emergency visits. Launch plans target key cardiology providers, with broad access and support programs in place.
-
Etripamil (Cardamyst) targets a large SVT market with FDA approval expected by year-end. Launch plans focus on retail access, affordable pricing, and payer engagement, with a staged rollout and strong physician adoption anticipated.
-
CARDAMYST is nearing FDA resubmission for PSVT after addressing CMC issues, with strong clinical data showing rapid conversion and reduced ED visits. Commercial launch preparations are complete, and expansion into AFib with RVR is planned, pending resources.
-
Etripamil (CARDAMYST) is nearing FDA approval for PSVT, with a commercial launch planned and a supplemental NDA for AFib-RVR to follow. The product targets a significant unmet need, offers rapid symptom relief, and is supported by strong clinical and financial positioning.
-
Cardamyst is positioned for a mid-2025 US launch pending FDA approval, targeting a large unmet need in PSVT with a fast-acting, self-administered nasal spray. The commercial strategy focuses on high-value cardiology prescribers, rational pricing, and broad payer access, with expansion into AFib and global markets planned.
Fiscal Year 2024
-
Etripamil, a nasal calcium channel blocker for acute PSVT, addresses significant unmet needs by offering rapid, self-administered relief for patients dissatisfied with current therapies. Experts anticipate broad adoption, especially for those with infrequent episodes and intolerance to chronic medications.